ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

Rhea-AI Summary

ObsEva SA, a clinical-stage biopharmaceutical company, announced the upcoming release of Phase 3 results from the PRIMROSE 1 and PRIMROSE 2 clinical trials on July 6, 2020. These trials focus on the treatment of heavy menstrual bleeding due to uterine fibroids using linzagolix. An investment community conference call is scheduled for the same day at 8 a.m. Eastern Time to discuss the results. ObsEva aims to enhance women's reproductive health through innovative therapies and is listed under the ticker symbol OBSV.

Positive

• Upcoming Phase 3 results may lead to significant advancements in treatment for uterine fibroids.
• Scheduled conference call allows investors to gain immediate insights into trial outcomes.

Negative

• None.

Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release Phase 3 results from the  PRIMROSE 1 and PRIMROSE 2 clinical trials of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday July 6, 2020. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday July 6, 2020  to discuss these results. 

Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 6673575.  A webcast of the conference call can be accessed via the Events Calendar under the “Investors” section of ObsEva’s website www.obseva.com.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com

+1 857 972 9347 Office
+1 781 366 5726 Mobile

 

Attachment

• Press Release in Pdf

FAQ

What are the PRIMROSE trials by ObsEva?

The PRIMROSE trials are Phase 3 clinical studies evaluating linzagolix for treating heavy menstrual bleeding due to uterine fibroids.

When will ObsEva announce the results of the PRIMROSE trials?

Results from the PRIMROSE 1 and PRIMROSE 2 trials will be announced on July 6, 2020.

How can I access the conference call regarding ObsEva's trial results?

Investors can dial (844) 419-1772 for U.S. callers or +1 (213) 660-0921 internationally to join the conference call.

What is the significance of the linzagolix trials for ObsEva?

The linzagolix trials are crucial for ObsEva as they could establish the company as a leader in treatments for uterine fibroids.